AHCC07

Completed recruitment of 147 patients in January 2021. (planned recruitment is 100), of which 132 patients have reached the study end-point (as defined by recurrence, death or completion of 2 year follow-up from date of surgery).

Two main publications in Cell (DOI: 10.1016/j.cell.2020.08.040) and Nature Communications (DOI: 10.1038/s41467-020-20171-7).

Patent:

1. A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient (Valerie Chew, Pierce Chow, Albani Salvatore) (Application number: 10201709924T; Filing Date: 30/11/2017)
2. Cell-based biomarkers of immunotherapy in hepatocellular carcinoma (Ankur Sharma, Florent Ginhoux, Ramanuj Dasgupta, Pierce Chow) (Singapore Provisional Application number.: 10202007868Q; Filing Date: 17/08/2020)

Malaysia

Yoong Boon Koon (University Malaya Medical Center)

Philippines

Maria Vanessa H. de Villa (The Medical City)

Singapore

Pierce Chow (National Cancer Centre), Glenn Bonney (National University Hospital), Brian Goh (Singapore General Hospital)

Thailand

Rawisak Chanwat (National Cancer Institute)

United States of America

Sabino Zani Jr (Duke University School of Medicine)

Theme: Genomic evolution in HCC and the discovery of novel drug targets

Name: Zhai Weiwei

Designation: Senior Research Scientist

Institution: Genome Institute of Singapore

Theme: Translational Immunomics: Immune-phenotyping, monitoring and discovery of novel immunotherapies

Name: Salvatore Albani

Designation: Director

Institution: SingHealth Translational Immunology and Inflammation Centre

Theme: Clinical Trajectory and Translational Therapeutics

Name: Pierce Chow

Designation: Senior Consultant

Institution: National Cancer Centre

Pierce Chow
pierce.chow@duke-nus.edu.sg